Molecular insights into protein synthesis with proline residues

Sergey Melnikov¹,²,†, Justine Mailliot¹,²,†, Lukas Rigger³, Sandro Neuner³, Byung-Sik Shin⁴, Gulnara Yusupova¹,², Thomas E Dever⁴,*, Ronald Micura³,** & Marat Yusupov¹,²,***

Abstract

Proline is an amino acid with a unique cyclic structure that facilitates the folding of many proteins, but also impedes the rate of peptide bond formation by the ribosome. As a ribosome substrate, proline reacts markedly slower when compared with other amino acids both as a donor and as an acceptor of the nascent peptide. Furthermore, synthesis of peptides with consecutive proline residues triggers ribosome stalling. Here, we report crystal structures of the eukaryotic ribosome bound to analogs of mono- and di-prolyl-tRNAs. These structures provide a high-resolution insight into unique properties of proline as a ribosome substrate. They show that the cyclic structure of proline residue prevents proline positioning in the amino acid binding pocket and affects the nascent peptide chain position in the ribosomal peptide exit tunnel. These observations extend current knowledge of the protein synthesis mechanism. They also revise an old dogma that amino acids bind the ribosomal active site in a uniform way by showing that proline has a binding mode distinct from other amino acids.

Keywords hydrolysis-resistant aminoacyl-tRNA analogs; peptide bond formation; proline; protein synthesis; ribosome

Subject Categories Protein Biosynthesis & Quality Control; Structural Biology

DOI 10.15252/embr.201642943 | Received 23 June 2016 | Revised 28 September 2016 | Accepted 30 September 2016

Introduction

Among the ~20 amino acids that comprise all proteins in a living cell, proline stands out as the only residue in which the side chain is covalently attached to the α-amine, forming a rigid cyclic structure. This proline structure facilitates folding of many proteins by introducing rigid turns into the peptide chain and by setting borders of β-sheets and α-helices [1,2]. Also, peptides with consecutive proline residues fold into a characteristic polyproline helix (P II-helix), which constitutes a common protein–protein interaction motif and also endows proteins with unique mechanical properties [3,4].

However, numerous studies show that, although the unique chemical structure of proline facilitates protein folding, it also markedly impedes the rate of peptide bond formation by the ribosome. When proline is used for protein synthesis—either as a peptidyl donor in ribosomal P-site [5–7] or as a peptidyl acceptor in ribosomal A-site [7–9]—it reacts markedly slower than other amino acids. Most interestingly, the inhibitory effect of proline on protein synthesis becomes progressively stronger when peptides with consecutive proline residues must be produced by the ribosome [10–12]. Thus, synthesis of peptides with three or more consecutive prolines provokes ribosome stalling [10–12].

In a living cell, ribosome stalling by polyproline sequences is resolved by a universally conserved translation factor, known as eIF5A in eukaryotes and EF-P in bacteria [10–12]. In eukaryotes, eIF5A alleviates ribosome stalling by contacting the acceptor stem of the P-site tRNA, using a mechanism that is not yet fully understood [13,14]. The presence of eIF5A in eukaryotic cells enables synthesis of proteins containing polyproline motifs. This factor is essential because polyproline motifs are highly abundant in eukaryotic proteomes. Human proteome, for example, contains ~10,000 motifs with three or more consecutive proline residues, with some proteins having up to 27 consecutive prolines [1,2].

Extensive kinetic studies of peptide bond formation with proline suggested that proline impedes the rate of protein synthesis by increasing entropy of peptide bond formation [7]. Furthermore, cryoelectron microscopy analysis of ribosome complexes with stalling peptides revealed the position of proline residues in the ribosomal P-site during translational stalling [15–17]. These studies profoundly extended our understanding of protein synthesis chemistry with proline. However, the conformation of proline and its reactive groups in the peptidyl transferase center is still unknown.

---

1 Institute of Genetics and Molecular and Cellular Biology, CNRS UMR7104, INSERM UMR964, Illkirch, France
2 Strasbourg University, Strasbourg, France
3 Institute of Organic Chemistry, Leopold Franzens University, Innsbruck, Austria
4 Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
*Corresponding author. Tel: +1 301 496 4538; E-mail: thomas.dever@nih.gov
**Corresponding author. Tel: +43 512 507 57710; E-mail: ronald.micura@uibk.ac.at
***Corresponding author. Tel: +33 388 65 3301; E-mail: marat@igbmc.fr
†These authors contributed equally to this work
and, therefore, it is unclear how proline slows down the rate of protein synthesis.

Seeking to address this question, we determined crystal structures of the yeast 80S ribosome, bound with prolyl- and diprolyl-tRNA analogs. These initial structures provide high-resolution snapshots of proline positioning in the active centers of the ribosome, such as the ribosomal A-site and the nascent peptide tunnel. Our data illustrate that the unique chemical structure of proline cycle has a dramatic impact on the proline position in the ribosomal active centers, preventing proline from adopting an optimal position required for rapid protein synthesis.

Results and Discussion

Synthesis of aminoacyl- and peptidyl-tRNA analogs and ribosome structure determination

To approach structural studies of protein synthesis with proline residues, we chemically synthesized aminoacyl- and dipeptidyl-tRNA analogs (Fig EV1). These analogs comprise the $A_{23}C_{74}C_{75}A_{236}$ tRNA acceptor stem with a 3'-amido (instead of the natural ester) linkage between $A_{23}$ and the C-terminus of the corresponding amino acid or dipeptide moiety to impede hydrolytic cleavage. Based on a novel 3'-prolylamino-3'-deoxyadenosine solid support (Fig EV1), we produced the ribosome substrates ACCA-Pro and ACCA-Pro-Pro. For reasons of comparison, we additionally produced the ribosome substrates ACC-puromycin and ACC-Leu-Phe using previously described strategies [18,19].

Our choice of amido variants of aminoacyl-tRNA analogs was based not only on the fact that these analogs are hydrolysis resistant and therefore, compatible with crystallization conditions, but also because they were shown to functionally mimic natural ribosome substrates. In particular, it was previously shown that amido derivatives of aminoacyl-tRNA mimics adopt the same conformation in the peptidyl transferase center as natural aminoacyl-tRNAs [20].

Having synthesized the ribosome substrates, we determined the crystal structures of these substrates bound to the Saccharomyces cerevisiae 80S ribosome. The ribosome structures bound with the A-site ACCA-proline ($\ell/\sigma = 1$ at 3.3 Å) or with ACC-puromycin (ACCM$^2$A-methyl tyrosine) ($\ell/\sigma = 1$ at 3.25 Å) (Table EV1, Fig 1A and B) were determined after rapid soaking of preformed ribosome crystals in a 100 μM substrate solution (Materials and Methods). Similarly, the ribosome structures bound with P-site ACCA-prolineproline ($\ell/\sigma = 1$ at 3.1 Å) and ACCA-leucine-phenylalanine ($\ell/\sigma = 1$ at 3.5 Å) were determined after soaking of ribosome crystals in 100 μM substrate solution supplemented with 300 μM the antibiotic sparsomycin. Sparsomycin was used to stabilize binding of the peptidyl-tRNA analogs in the ribosomal P-site [20–22] (Table EV1, Fig 1C and D).

Our attempts to simultaneously bind aminoacyl- and peptidyl-tRNA analogs to the A-site and P-site, respectively, resulted in datasets in which only aminoacyl-tRNA analogs were observed in the A-site, whereas the P-site remained vacant. These results were similar to the previous studies of the ribosomal complexes with partial tRNA analogs [20–22]. This possibly reflects a relatively weak affinity of the CCA moiety to the ribosomal P-site [20–22].

Collectively, we obtained four ribosome crystal structures in which either the A-site or the P-site was occupied by a model aminoacyl- or dipeptidyl-tRNA analog (Table EV1).

Proline in the ribosomal A-site

Ribosomes with the aminoacyl-tRNA analogs bound to the A-site have a similar resolution of ~3.3 Å (Table EV1). The electron density maps reveal the CCA fragment bound with the A-loop of 25S rRNA, as well as aminoacyl moieties bound with the amino acid binding pocket of the ribosome (Fig 1A and B).

Although the ribosomal P-site remains vacant in these crystal structures, previous studies showed that the P-site tRNA binding has a relatively minor effect on the aminoacyl moiety conformation in the ribosomal A-site [20,22]. Therefore, we used these structures to gain insight into a possible position of proline residue in the ribosomal A-site during protein synthesis.

In the ribosome structure with the ACC-puromycin (ACCM$^2$A-methyl tyrosine), the puromycin moiety has a nearly identical conformation to those observed in prokaryotic ribosomes in the pre-attack state of the peptide bond formation [21,23] (Figs 2A and EV2). In this conformation, the $\alpha$-amine is directed toward the peptidyl-tRNA, whereas the amino acid chain flips away from the P-site and remains bound to the conserved hydrophobic cavity of the ribosome, the A-site cleft (Figs 2A and EV2). While bound to the A-site cleft, the amino acid side chain remains physically separated from the actual site of the peptide bond formation by the conserved nucleotide A2820 of the yeast 25S rRNA (A2451 of the E. coli 23S rRNA).

In the ribosome structure with the ACCA-Pro, the proline moiety has a strikingly different and until now unknown conformation of an amino acid in the ribosomal A-site compared to the typically uniform binding of other amino acids. Unlike methyl tyrosine and other amino acids observed in the A-site [24], the proline side chain does not occupy the A-site cleft, but instead flips toward the ribosomal P-site (Fig 2B). In this conformation, the side chain of the proline residue penetrates the actual site of the peptide bond formation (Fig 2B). It is likely that in this position, the side chain may prevent proper alignment of the A-site and P-site substrates in the active site of the ribosome.

Additionally, compared to other amino acids, the $\alpha$-amino group of the proline residue is displaced by ~1 Å from the ribosomal P-site (Fig EV3). In this conformation, proline may have an unusual orientation of the reactive electron pairs in the $\alpha$-amine group: The tetrahedral electron pair geometry and limited flexibility of the proline cycle suggest that proline’s electron pair should deviate from the favorable position required for optimal nucleophilic attack (Fig 2B).

Thus, proline conformation in the ribosomal A-site suggests that the poor reactivity of proline as a peptidyl acceptor originates from two factors: the unfavorable orientation of the $\alpha$-amine and its reactive electron pair as well as the binding of the proline side chain to the outside of the A-site cleft of the ribosome. Both of these factors appear to prevent the optimal alignment of substrates in the peptidyl transferase center of the ribosome. Notably, despite proline’s side chain not entering the A-site cleft of the ribosome and adopting a highly unusual conformation, the $\alpha$-amine of proline remains accessible for the peptide bond formation and has a position in the
peptidyl transferase center comparable to the ones observed for other amino acids, illustrating why proline remains reactive, although at an order of magnitude slower rate when it is compared to other proteinogenic amino acids [7–9].

**Figure 1.** Structures and electron density maps of the ribosome-bound aminoacyl- and dipeptidyl-tRNA analogs.
The refined models of four crystal structures of the ribosome bound to aminoacyl- or peptidyl-tRNA analogs are displayed in their respective unbiased electron density $F_o-F_c$ maps (contoured at 2.5 $\sigma$). The maps were calculated using phases produced by rigid body refinement of the ligand-free test structure put into the $F_o$ dataset.

A, B A-site-bound substrates ACC-puromycin (A) and ACCA-Pro (B).
C, D P-site-bound substrates ACCA-Leu-Phe (C) and ACCA-Pro-Pro (D).

Data information: The insets in each panel indicate position of a ligand relative to the A-site (in yellow) and P-site (in green) of the ribosome; the actual binding site of each ligand is highlighted in red.

Diprolyl peptide in the ribosomal nascent peptide exit tunnel
Ribosome structures with dipeptidyl-tRNA analogs bound to the P-site have a comparable resolution of 3.1–3.5 Å (Table EV1).
The electron density maps reveal the CCA fragment bound to the P-loop of 25S rRNA, as well as the dipeptidyl moieties at the entrance to the ribosomal nascent peptide exit tunnel (Fig 1C and D).

The antibiotic sparsomycin, which we used in this study to stabilize P-site substrates on the ribosome, was described to deform the A76 sugar pocket and the carbonyl group in the P-site peptidyl-tRNA [20]. Therefore, the crystal structures did not reveal the functional state of these critical groups in the P-site ligands. However, sparsomycin does not affect the overall peptide chain conformation of the model dipeptides [20]. Therefore, we used our structures to gain insights into how dipeptides Pro-Pro and Leu-Phe are positioned in the nascent peptide-conducting tunnel.

In the ribosome structure with the ACCA-Leu-Phe ligand, the Leu-Phe peptide enters the tunnel in a way similar to the short model peptides observed earlier [20,22]. The Phe residue appears to be partially disordered, reflecting conformational flexibility of this moiety in the peptide exit tunnel (Fig 3A).

In the ribosome structure with ACCA-Pro-Pro ligand, the observed diprolyl peptide structure is bent: The N-terminus of the diprolyl peptide is oriented toward the nascent tunnel wall instead of being directed directly into the tunnel (Fig 3B). It is important to note that this bent conformation reflects unique stereochemical constraints for the pyrrolidine ring of a proline residue (Fig EV4). Consistently with these constraints, the diprolyl peptide has parameters of the trans-polyproline helix (P\textsubscript{II}-helix) (Fig EV4).

The electron density maps reveal the CCA fragment bound to the P-loop of 25S rRNA, as well as the dipeptidyl moieties at the entrance to the ribosomal nascent peptide exit tunnel (Fig 1C and D).

The antibiotic sparsomycin, which we used in this study to stabilize P-site substrates on the ribosome, was described to deform the A76 sugar pocket and the carbonyl group in the P-site peptidyl-tRNA [20]. Therefore, the crystal structures did not reveal the functional state of these critical groups in the P-site ligands. However, sparsomycin does not affect the overall peptide chain conformation of the model dipeptides [20]. Therefore, we used our structures to gain insights into how dipeptides Pro-Pro and Leu-Phe are positioned in the nascent peptide-conducting tunnel.

In the ribosome structure with the ACCA-Leu-Phe ligand, the Leu-Phe peptide enters the tunnel in a way similar to the short model peptides observed earlier [20,22]. The Phe residue appears to be partially disordered, reflecting conformational flexibility of this moiety in the peptide exit tunnel (Fig 3A).

In the ribosome structure with ACCA-Pro-Pro ligand, the observed diprolyl peptide structure is bent: The N-terminus of the diprolyl peptide is oriented toward the nascent tunnel wall instead of being directed directly into the tunnel (Fig 3B). It is important to note that this bent conformation reflects unique stereochemical constraints for the pyrrolidine ring of a proline residue (Fig EV4). Consistently with these constraints, the diprolyl peptide has parameters of the trans-polyproline helix (P\textsubscript{II}-helix) (Fig EV4).

The observation that diprolyl peptide has parameters of the P\textsubscript{II}-helix may have important implications for studies of co-translational protein folding. The diprolyl peptide structure suggests that P\textsubscript{II}-helices are formed simultaneously with the formation of peptide bonds between consecutive proline residues. Because P\textsubscript{II}-helix is the third most common secondary structure element after \(\beta\)-sheets and \(\alpha\)-helices [27], it will be interesting to study whether P\textsubscript{II}-helices can indeed be formed in the ribosomal tunnel and how it passes along the tunnel during protein synthesis.
Perspectives

Beyond insights into protein synthesis with proline, our data revise old dogmas suggesting that amino acids bind the ribosomal active site in a uniform way [24]. Proline’s position in the ribosomal A-site illustrates that side chain structure may have a tremendous impact on amino acid positioning in the ribosomal active site. Proline position also demonstrates that amino acids have more than a single mode by which to bind the peptidyl transferase center.

In summary, our study provides ribosome structures which describe proline binding within the functional centers of the ribosome: the ribosomal A-site and the peptide tunnel. In the future, this study may impact not only the field of protein synthesis, but also the emerging field of synthetic biology in which synthetic amino acids are used for protein synthesis to expand the chemistry of living systems [28–30]. The knowledge of how amino acid’s structure affects its binding to the ribosome may enable rational design of unnatural ribosome substrates and remodeling of the ribosome active sites to enable rapid protein synthesis with unnatural substrates.

Materials and Methods

Synthesis of hydrolysis-resistant aminoacyl- and peptidyl-tRNA analogs

As the presence of STM1 protein in the P-site of our yeast ribosome crystals blocks access of full-length tRNAs [31], we produced partial aminoacyl-tRNA and dipeptidyl-tRNA analogs, using A73C74C75A76 RNA moiety and introduced a 3’-amido linkage between A76 and the C-terminus of the dipeptyl moiety to prevent hydrolysis of this analog during crystallization. While eukaryotic tRNAPro typically contains C rather than A at residue 73, this residue does not interact with the ribosome and, consistently, does not affect the tRNA position on the ribosome.

The ACC-puromycin conjugate was produced as previously described [32]. The ACCA-Leu-Phe conjugate was produced according to the following references [33,34]. The ACCA-Pro-Pro and ACCA-Pro conjugates were produced as outlined in Fig EV1 and as described below:

Compound 2: N⁶-[(Di-n-butylamino)methylene]-3’-[N-(9-fluorenyl)methoxycarbonyl-L-prolyl] amino-3’-deoxy-5’-O-(4,4’-dimethoxytrityl)-D-adenosine. Fmoc-protected proline (84 mg, 0.25 mmol) was dissolved in 3 ml DMF followed by addition of O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU, 94 mg, 0.25 mmol), 1-hydroxybenzotriazole hydrate (HOBt, 38 mg, 0.25 mmol), and N,N-diisopropylethylamine (DIPEA, 50 μl, 0.29 mmol). After 3 min of activation, 3’-amino-N⁶-[(di-n-butylamino)methylene]-3’-deoxy-5’-O-(4,4’-dimethoxytrityl)-D-adenosine 1 [35] (135 mg, 0.19 mmol, in 1 ml DMF) was added and the mixture was stirred overnight at room temperature. Then, the solvent was evaporated, the residue dissolved in CH₂Cl₂ and washed consecutively with half-saturated aqueous NaHCO₃ solution, 5% citric acid solution, and saturated NaCl solution. The organic layer was dried (Na₂SO₄) and evaporated, and the crude product was purified via SiO₂ chromatography yielding 150 mg of compound 2 as white foam (76%). TLC (6% MeOH in CH₂Cl₂) Rₜ = 0.4. 1H NMR (300 MHz, CDCl₃) δ 9.02 (s, 1H, HC = N(6)), 8.44 (s, 1H, HC(2)),

Figure 3. Diprolyl peptide has a bent conformation in the nascent peptide exit tunnel of the ribosome.

A, B This figure compares conformation of two dipeptides in the ribosome nascent peptide tunnel: Phe-Leu peptide (A), and Pro-Pro peptide (B). In both illustrations, the arrow points to the α-amine of the N-terminal residue. Comparison of the two structures reveals that the N-terminus of the Phe-Leu peptide is directed into the tunnel, whereas the N-terminus of the Pro-Pro peptide is directed toward the wall of the tunnel.

© 2016 The Authors

EMBO reports
8.09 (s, 1H, HC(8)), 7.73 (m, 2H, HC(ar)), 7.54 (d, 1H, J = 7.3, HC(ar)), 7.33–7.16 (m, 14H, HC(ar)), 6.98 (s, 1H, CN(3)), 6.75 (d, 4H, J = 7.2), 6.00 (s, 1H, HC(1′)), 4.83 (s, 1H, HC(2′)), 4.70 (m, 1H, HC(3′)), 4.37 (m, 3H, HC(4′) and OCH2(Fmoc)), 4.22 (m, 2H, HC(9, Fmoc) and HC(8, Pro)), 3.75 (s, 6H, 2xOCH3(DMT)), 3.71 (m, 2H, N(CH2CH2CH2CH3)2), 3.57 (m, 2H, CH2(Pro)), 3.43 (m, 4H, N(CH2CH2CH2CH3)2) and N(CH2CH2CH2CH3)2), 2.16–1.91 (m, 4H, 2xCH2(Pro)), 1.66 (m, 4H, N(CH2CH2CH2CH3)2), 1.35 (m, 4H, N(CH2CH2CH2CH3)2), 0.94 (m, 6H, N(CH2CH2CH2CH3)2).

13C NMR (75 MHz, CDCl3) δ 158.6 (HC(O)), 128.4–125.0 (C(ar)), 120.2 (C(ar)), 113.3 (C(ar)), 86.8 (C(1)), 74.7 (C(2′)), 68.0 (OCH2(Fmoc)), 63.8 (C(5′)), 60.8 (C(α, Pro)), 55.3 (2xOCH3), 53.5 (C(3′)), 52.0 (N(CH2CH2CH2CH3)2), 46.5 (HC(y, Pro)), 45.3 (N(CH2CH2CH2CH3)2), 31.1 (N(CH2CH2CH2CH3)2), 29.4 (CH2, Pro), 25.0 (CH2(Pro)), 20.3 and 19.9 (N(CH2CH2CH2CH3)2), 14.0 and 13.8 (N(CH2CH2CH2CH3)2).

ESI-MS (m/z): [M+H]+ calcd for C60H67N8O8, 1027.51; found 1027.50.

Compound 3: N6-[Di-n-butylamino)methylene]-3’-N(9-fluoren-9-ylmethoxy)carbonyl-L-prolyl amino-3’-deoxy-5’-O-(4,4’-dimethoxytrityl)-2’-O-[1,6-dioxo-6-(pentafluorophenyl)-D-adenosine (130 mg, 0.09 mmol) was dissolved in dry DMF (200 mg, 0.19 mmol) in DMF and pyridine (20 ml) and agitated for 10 min at room temperature. The suspension was filtered again, the beads were washed with THF, methanol, and CH2Cl2 and dried under vacuum. The loading of the support was 45 μmol/g.

Solid-phase peptide synthesis on the solid support 4

In a frit-fitted syringe, the solid support 4 (80 mg) was soaked with dry DMF (2 ml, 30 min). For deprotection of the Nα-Fmoc group, the solid support was treated two times with piperidine solution (20% in DMF, 1.5 ml, 8, 12 min) and subsequently washed with DMF (3 × 2 ml). Coupling was performed by treating the solid support for one hour with a mixture of Fmoc-proline solution (0.4 M in DMF, 500 μl), activator solution (HBTU and HOBr, 0.6 M in DMF, 750 μl), and DIPEA (140 μl). This step was performed twice. Then, the solid support was washed with DMF (3 × 2 ml) and acetonitrile (3 × 2 ml) and vacuum-dried.

RNA synthesis

The ACCA moiety was assembled on an ABI 392 Nucleic Acid Synthesizer following standard synthesis protocols. Detritylation (120 s): dichloroacetic acid/1,2-dichloethane (4/96); coupling (120 s): phosphoramidites (0.1 M in acetonitrile, 130 ml) were activated with benzylthiotetrazole (0.3 M in acetonitrile, 180 μl); capping (2 × 10 s, Cap A/Cap B = 1/1): Cap A: phosphoramidite acetylhydride (0.2 M in THF); Cap B: N-methyl imidazole (0.2 M), sym-collidine (0.2 M) in THF; oxidation (20 s): I2 (0.2 M) in THF/pyridine/H2O (35/10/5). Amidites, benzylthiotetrazole, and capping solutions were dried over activated molecular sieves (4 Å) overnight.

Final product

Deprotection of the 3′-dipropyl-ACCA conjugate. A) Fmoc deprotection. In the ABI synthesis column, the solid support was treated with a solution of 20% piperidine in acetonitrile (10 ml, 10 min), washed with acetonitrile, and dried. B) Acyl deprotection and cleavage from the solid support. For the conjugates synthesized on solid support 4, the beads were transferred into an Eppendorf tube and equal volumes of methylamine in ethanol (8 M, 0.5 ml) and methylamine in H2O (40%, 0.5 ml) were added. After 6 h shaking at room temperature, the supernatant was filtered and evaporated to dryness. C) 2’-O-TOM deprotection. The obtained residue was treated with TBAF 3 H2O in THF (1 M, 1 ml) overnight at room temperature. The reaction was quenched by the addition of triethylammonium acetate (TEAA) (1 M, pH 7.4, 1 ml). After reducing the volume of the solution, it was applied on a size-exclusion chromatography column (GE Healthcare, HiPrep 26/10 desalting, 2 × 10 cm, Sephadex G25). By eluting with H2O, the conjugate-containing fractions were collected and evaporated to dryness, and the residue was dissolvo in H2O (1 ml). Analysis of the crude products was performed by anion-exchange chromatography on a Dionex DNA Pac PA-100 column (4 × 250 mm) at 60°C. Flow rate: 1 ml/min; eluent A: 25 mm Tris–HCl (pH 8.0), 6 M urea; eluent B: 25 mM Tris–HCl (pH 8.0), 0.5 M NaClO4, 6 M urea; gradient: 0–60% B in A within 45 min or 0–40% B in A within 30 min, UV detection at λ = 260 nm.
Purification of the 3′-diprol-ACCA conjugate

The crude conjugate was purified on a semipreparative Dionex DNAPac PA-100 column (9 × 250 mm) at 60°C with flow rate of 2 ml/min (for eluents, see above). Fractions containing the conjugate were loaded on a C18 SepPak Plus cartridge (Waters/Millipore), washed with 0.1 M (Et₃NH)⁺HCO₃⁻/H₂O, and eluted with H₂O/CH₃CN (1:1). Conjugate-containing fractions were evaporated to dryness and dissolved in H₂O (1 ml). The quality of the purified conjugate was analyzed by analytical anion-exchange chromatography (for conditions, see above). The molecular weight of the synthesized conjugate was confirmed by LC-ESI mass spectrometry (see Fig EV1B). Yields were determined by UV photometrical analysis of conjugate solutions. The final compound was dissolved in water to achieve ~50 mM concentration for stock solutions and later used for soaking.

Ribosome purification, crystallization, crystal treatments

80S ribosomes from the yeast *S. cerevisiae* were purified, crystallized, and treated essentially as previously described [14,31]. Ribosome complexes, containing ACCA analogs, were formed by soaking with 100 μM of the corresponding compound and 300 μM of sparsomycin for ~2 h at 4°C in a buffer containing 80 mM Tris-acetate pH 7.0, 70 mM KSCN, 10 mM Mg(OAc)₂, 20% v/v glycerol, 15% w/v/PEG 20,000, 6.5 mM spermidine, 7.5 mM NH₄OAc, 1.4 mM deoxy-big-chap, 2 mM DTT before the transfer into a cryoprotecting buffer containing 80 mM Tris-acetate pH 7.0, 70 mM KSCN, 10 mM Mg(OAc)₂, 18% v/v glycerol, 20% w/v PEG 20,000, 6.5 mM spermidine, 7.5 mM NH₄OAc, 20% w/v/PEG 6,000, 2 mM Os(NH₂)₆Cl₃.

Data collection and processing

Diffraction data were collected from crystals cooled to 90°K using 0.1° oscillation range and the beam-line Proxima 1 at the Synchrotron Soleil (France). We used a data collection strategy developed at Swiss Light Source Synchrotron (Switzerland), which exploits the unique features of the single photon counting pixel detector PILATUS 6M [31,36,37]. During data collection, the beam was attenuated to 3–10% of its maximum flux. This was done to markedly reduce radiation damage and collect a highly redundant dataset from multiple spots of each crystal. Then, data were processed and reduced by the XDS suite [38], yielding the statistics displayed in Table EV1.

Because of highly attenuated beam, this data collection strategy results in unconventionally high R_meas values when it is compared to CCD-detector type data collection strategies (no beam attenuation, no fine φ-slicing, low data redundancy). However, it provides more accurate values for reflections’ intensities and anomalous signal when single photon counting pixel detectors are used for data collection [37,39].

Structure determination, refinement, validation, and analyses

The structures were determined by molecular replacement using the vacant yeast 80S ribosome structure (pdb 4v88) as a search model and then subjected to refinement using Phenix.refine [40]. Restraints for ACCA analogs and sparsomycin were generated with JLigand [41] and ReadySet from the Phenix suite [40].

Ligands building, fitting, remodeling of ribosomal binding sites and analysis of Ramachandran plots were performed using Coot [42]. Ribosome structure and ligand geometry (torsion angles, bond lengths, and bond angles) were refined using Phenix.refine [40]. Crystallographic statistics are reported in Table EV1. Ligands geometry was validated with the software Molprobity [44]. Figures were prepared using PyMOL (Schrödinger LLC).

Expanded View for this article is available online.

Acknowledgements

We are grateful to Petr Sergiev (Lomonosov Moscow State University) for providing us with sparsomycin; to the staff of Proxima 1 beamline at the synchrotron SOLEIL (France), and in particular to Andrew Thompson and Pierre Legrand for providing rapid access to the beam and for assisting with data collection, and to members of T.D., R.M., and M.Y. teams for insightful and inspiring discussions! We also thank Conwin Miller and members of Tom Steitz and Dieter Söll laboratories (Yale University) for critically reading and commenting on the manuscript. We also thank Catherine Dunlavey (University of St. Andrews, UK) for editorial support during the manuscript preparation. This work was supported by Foundation pour la Recherche Médicale en France SPF20111223404 (to S.M.), the Austrian Science Fund FWF (P21641 and I040 to R.M.), the French National Research Agency ANR-15-CE11-0021-01 (to G.Y.), the European Research Council advanced grant 294312 and the Human Frontier Science Program grant RGP0062/2012 (both to M.Y.), the Russian Government Program of Competitive Growth of Kazan Federal University (both to M.Y. and G.Y.), and in part by the Intramural Research Program of the National Institutes of Health, NICHD (T.D.). The structures were deposited to the protein data bank with accession codes 5dvx, 5lyb, 5tga, and 5tgm.

Author contributions

SM, MY, TED, and RM devised experiments; LR and SN produced tRNA conjugates; JM crystallized ribosomal complexes and performed the soaking; JM and SM performed crystallographic data collection and processing, SM and JM analyzed crystallographic data; SM, JM, LR, SN, B-SS, GY, TD, RN and MY wrote and commented on the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

References


